中国原发性醛固酮增多症高血压患者的全国性筛查和登记。
China nationwide screening and registry of primary aldosteronism in hypertensive patients.
机构信息
Department of Hypertension, Ruijin Hospital North, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
出版信息
J Hum Hypertens. 2021 Feb;35(2):157-161. doi: 10.1038/s41371-020-00458-4. Epub 2021 Jan 18.
In the framework of the China Hypertension Control Initiatives, the China Primary Aldosteronism Prospective Study was designed as a nationwide multicenter programme for the screening and registry of primary aldosteronism in hypertensive patients. The primary objective was to establish technological platforms, team and expertise for the screening, diagnosis and treatment of primary aldosteronism in cardiology outpatient clinics. From 18 July 2018 to 31 May 2020, 1329 patients from 14 cities had been screened. 348 (26.2%) patients had a plasma aldosterone-to-renin ratio of ≥40 (pg/ml)/(pg/ml) and enroled in the registry. 175 (50.3%) patients had confirmatory testing, of whom 163 (93.1%) had a confirmed diagnosis of primary aldosteronism.
在中国高血压控制计划的框架下，中国原发性醛固酮增多症前瞻性研究设计为一项全国多中心计划，旨在筛查和登记高血压患者中的原发性醛固酮增多症。主要目标是为心内科门诊的原发性醛固酮增多症筛查、诊断和治疗建立技术平台、团队和专业知识。自 2018 年 7 月 18 日至 2020 年 5 月 31 日，已有来自 14 个城市的 1329 名患者接受了筛查。348 名（26.2%）患者的血浆醛固酮/肾素比值≥40（pg/ml）/（pg/ml），并登记在该注册中。175 名（50.3%）患者进行了确认性检查，其中 163 名（93.1%）患者确诊为原发性醛固酮增多症。
Zotero 插件